MARKET

CDTX

CDTX

Cidara Theraptcs
NASDAQ
0.7122
+0.0047
+0.66%
After Hours: 0.7200 +0.0078 +1.10% 16:12 03/01 EST
OPEN
0.7118
PREV CLOSE
0.7075
HIGH
0.7388
LOW
0.7041
VOLUME
238.42K
TURNOVER
0
52 WEEK HIGH
2.100
52 WEEK LOW
0.5930
MARKET CAP
64.41M
P/E (TTM)
-1.8327
1D
5D
1M
3M
1Y
5Y
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
NASDAQ · 4d ago
Weekly Report: what happened at CDTX last week (0219-0223)?
Weekly Report · 6d ago
Weekly Report: what happened at CDTX last week (0212-0216)?
Weekly Report · 02/19 10:35
12 Health Care Stocks Moving In Wednesday's After-Market Session
KalVista Pharma (NASDAQ:KALV) stock moved upwards by 11.0% to $15.99 during Wednesday's after-market session. The company's, Q4 earnings came out today. Anitra stock increased by 9.25% and CytoMed Therapeutics stock rose 7.5% in the same session. Beyond Air stock fell 8.11% and Adaptive Biotechnologies stock declined by 8.6%.
Benzinga · 02/14 21:31
Cidara receives $11M milestone payment from partner Mundipharma
Cidara receives $11M milestone payment from partner Mundipharma. European approval of its antifungal drug Rezzayo for the treatment of invasive candidiasis in adults. Cidara said the payment will help advance its Cloudbreak platform for the development of drug conjugates.
Seeking Alpha · 02/12 19:26
Cidara Receives Milestone Payment From Mundipharma On European Approval Of REZZAYO
NASDAQ · 02/12 13:19
Weekly Report: what happened at CDTX last week (0205-0209)?
Weekly Report · 02/12 10:29
Cidara Therapeutics Granted Nasdaq Listing Extension
TipRanks · 02/10 09:05
More
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.

Webull offers Cidara Therapeutics Inc stock information, including NASDAQ: CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.